 | • レポートコード：MRC2106A159 • 出版社/出版日：Mordor Intelligence / 2021年5月25日 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査資料は、世界のホルモン補充療法市場について調査し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、治療法別（エストロゲン補充、成長ホルモン補充、甲状腺ホルモン補充、テストステロン補充）分析、投与経路別（経口、非経口、その他）分析、疾患別（更年期障害、甲状腺機能低下症、成長ホルモン欠乏症、その他）分析、地域別分析、競争状況、市場機会/将来の見通しなどを徹底分析したものです。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界のホルモン補充療法市場規模：治療法別（エストロゲン補充、成長ホルモン補充、甲状腺ホルモン補充、テストステロン補充） ・世界のホルモン補充療法市場規模：投与経路別（経口、非経口、その他） ・世界のホルモン補充療法市場規模：疾患別（更年期障害、甲状腺機能低下症、成長ホルモン欠乏症、その他） ・世界のホルモン補充療法市場規模：地域別 ・競争状況 ・市場機会/将来の見通し |
The Hormone Replacement Therapy Market was valued at approximately USD 17,376.73 million in 2020 and is expected to witness a revenue of USD 26,847.46 million by 2026, with a CAGR of 7.59% over the forecast period.
The COVID-19 pandemic is expected to have a significant impact on the home replacement therapy market. There has been an increasing number of research studies being carried out to find the application of hormone replacement therapy in COVID-19 infected patients. For instance, as per the research article published in BMC Medicine, 2020, the survival rate was in post-menopausal women who are infected with SARS-CoV-2 was found to be high, who were on a regular dose of exogenous estradiol for postmenopausal complaints. Additionally, a phase 2 clinical trial was initiated by the Stony Brook University, in April 2020, to evaluate the role of estrogen in reducing the severity of COVID19 symptoms compared to regular care, with the administration of estradiol through a transdermal patch for a short duration of 7 days. Hence, owing to the aforementioned factors, Hormone replacement therapy is expected to play a promising role in the development of novel therapeutics for the effective treatment against SARS-CoV2 virus infection, which in turn leads to the growth of the studied market during the pandemic.
Certain factors that are positively affecting the Hormone Replacement Therapy (HRT) market growth are increasing awareness on post-menopausal issues among women, rise in drug development with novel delivery systems, and hormonal imbalance disorders with the rising geriatric population.
According to the United Nations, World Population Ageing, 2019 report, as of 2050, women population is estimated to comprise 54 per cent of the global population aged 65 or over, with a life expectancy at birth of 74.7 years in 2019. With various kinds of hormonal changes, the female body predominantly gets affected by the natural process of aging, leading to abnormalities and diseases. Some of the common problems include weight gain, memory decline, fatigue, low libido, aging appearance, and muscle loss.
The most frequently reported consequence of age-related hormonal changes occurs in cases related to menopause. The global average onset age for menopause among women is approximately 50 years. In women, by the age of 50 years and above, the production levels of estrogen and progesterone decrease significantly. The decrease in production levels of estrogen and progesterone are compensated by the pituitary gland, with the increased production of follicle-stimulating hormone (FSH). This is physically manifested in women in the form of post-menopause symptoms, which include flush. These factors associated with age lead to the rising demand for HRT, thus driving the market studied.
Additionally, the growing research and development activities by the key players in the discovery of novel therapetics for treatment of hormonal imbalances and rising product approvals is expected to aid in the positive growth of the studied market over the forecast period. However, the high cost of hormone replacement therapy and the risk of developing cancers with HRTs is anticipated to hamper the market growth globally.
Key Market Trends
In Indication Menopause is Expected to Grow at Healthy CAGR over Forecast Period
Menopause is the time that marks the end of women’s menstrual cycles. It is diagnosed after a woman had gone 12 months without a menstrual period. Menopause can happen at an age ranging between 40stor 50s. Menopause is a natural biological process. Hormone replacement therapy improves the quality of life and prolongs life for many elderly women, whether it is initiated at menopause or much later. The therapy helps elderly women maintain their estrogen levels.
This application is expected to rise in the future as the geriatric population globally is increasing. As the women reach the end of the reproductive stage, the levels of estrogen lower, which could lead to mood swings, depression, and anxiety along with certain physical changes. Hormone replacement therapy, with estrogen hormone, plays a vital role in combating the complications associated with menopause in the aging women population. According to the research article published in the Journal of Menopausal Medicine, 2020, nearly 75% of women experience the symptoms of menopause between the age of 45-55 years, which has lead to a reduction of self-esteem among them. Hence, combination therapy of levonorgestrel releasing-intrauterine system (LNG-IUS) with oral or percutaneous estrogen, low-dose combined oral contraceptives (COCs), and estrogen-progestogen therapy (EPT) are usually suggested HRTs for treating the symptoms of menopause during the menopausal transition.
Additionally, the rise in product approvals is expected to drive the segment growth. For instance, in October 2018, US FDA approved bioidentical estradiol and progesterone capsules (Bijuva) of TherapeuticsMD as hormone therapy for menopausal women suffering from moderate to severe vasomotor symptoms. Thus, owing to the aforementioned factors the menopause indication segment is expected to witness significant growth over the forecast period.
North America Holds the Largest Market Share and is Expected to do the same Over the Forecast Period
The rising geriatric population is one of the primary factors responsible for the growth of the hormonal replacement therapy market in the North American region, especially in the United States and Canada.
According to the National Institutes of Health (NIH), almost half of all the postmenopausal women in the United States reported having used HRT at least once in their life. Also, according to a research article published in Statpearls, 2021, nearly 1.3 million American women enter into the menopause phase each year in the United States. The conjugated equine estrogens (CEE)/bazedoxifene tablet, a combination of estrogen and a selective estrogen receptor modulator, is available in the United States for menopausal VMS treatment and osteoporosis prevention.
Additionally, as per the American Thyroid Association (ATA), more than 12 percent of the population in the United States are predicted to experience a thyroid disorder during the lifetime, and nearly 20 million Americans being affected with some form of thyroid disease every year. Thus, the high incidence of thyroid hormone imbalance among the population in the United States is expected to boost the studied market in the region.
Also, in August 2020, US FDA approved Sogroya (somapacitan), a human growth hormone (hGH) therapy for adult patients with growth hormone deficiency and is indicated to be taken once a week by injection under the skin. Thus, the high trend of product approvals is also expected to drive the studied market in the region.
Overall, the market for HRT in North American is scheduled for high growth over the forecast period. The major drivers of this market are expected to increase the adoption of HRT among women, for both post-menopausal and menopause management.
Competitive Landscape
The market is moderately competitive with few major players dominating the market globally. The key companies are Abbott laboratories, Bayer AG, Merck KGaA, Novartis AG, and Pfizer Inc. However, there are efforts being made by new players to enter the hormone replacement therapy market. Additionally, the key players are focused on global product portfolio expansion through strategies such as acquisitions and collaborations with companies that complement the portfolio. For instance, in December 2020, US FDA approved Thyquidity (levothyroxine) oral solution, of VistaPharm, for replacement therapy of primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism, along with an additional approval as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Awareness on Post-menopausal Issues among Women
4.2.2 Rise in Drug Development with Novel Delivery Systems
4.2.3 Hormonal Imbalance Disorders with Rising Geriatric Population
4.3 Market Restraints
4.3.1 High Cost of Hormone Replacement Therapy
4.3.2 Substantial Risk of Cancer Associated with Hormone Replacement Therapy
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Therapy
5.1.1 Estrogen Hormone Replacement
5.1.2 Growth Hormone Replacement
5.1.3 Thyroid Hormone Replacement
5.1.4 Testosterone Replacement
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.2.3 Other Routes of Administration
5.3 By Indication
5.3.1 Menopause
5.3.2 Hypothyroidism
5.3.3 Growth Hormone Deficiency
5.3.4 Other Indications
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbott Laboratories
6.1.2 Bayer AG
6.1.3 Eli Lilly and Company
6.1.4 F. Hoffmann-La Roche
6.1.5 Merck KGaA
6.1.6 Mylan NV
6.1.7 Novartis AG
6.1.8 Novo Nordisk AS
6.1.9 Pfizer Inc.
6.1.10 Amgen
6.1.11 Genentech, Inc.
6.1.12 Abbvie Inc. (Allergan plc)
6.1.13 Teva Pharmaceutical Industries Ltd
6.1.14 Dr. Reddys Laboratories Ltd
7 MARKET OPPORTUNITIES AND FUTURE TRENDS